1652 (1652) Fair Value & Analysis

Healthcare · Market cap HK$747M

1 1652 1652 · HK

PriceHK$0.9400

Fair ValueHK$0.4500

Upside-52.1%

Quality57/100

Watch 1652 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$0.2600 – HK$0.6500

Fair value as of: Jul 2, 2026

From 12 valuation models · updated today

Share price −12.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.3150 – HK$1.59 · fair‑value band HK$0.2600 – HK$0.6500 · the HK$0.9400 price screens above the HK$0.4500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1652 (1652) currently trades at HK$0.9400, while our model-based Fair Value estimate is HK$0.4500 — implying the stock looks roughly 52.1% overvalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1652 generated revenue of HK$273M at a net margin of -4.3%. Revenue grew 25.0% year over year. It earns a return on equity of -3.3%. Net debt stands at HK$240M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$273M

Revenue growth (YoY) +25.0%

Net margin -4.3%

Return on equity -3.3%

Free cash flow HK$70.0M FY2025

Operating margin 6.8%

More key figures

EPS (TTM) HK$-0.0300

EPS growth (YoY) +42.6%

Net debt HK$240M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1652 reported revenue of HK$273M in FY2025 versus HK$386M in FY2021, a compound −8.2%/yr. Reported net income was −HK$11.8M in FY2025.

Revenue −8.2%/yr

FY21 HK$386M

FY22 HK$492M

FY23 HK$566M

FY24 HK$326M

FY25 HK$273M

Net income

FY21 HK$16.6M

FY22 −HK$34.7M

FY23 −HK$36.3M

FY24 −HK$189M

FY25 −HK$11.8M

Is 1652 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1652 (1652) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.4500 versus a price of HK$0.9400 — about −52% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1652?

Our model-based fair value for 1652 is HK$0.4500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.9400.

What is the quality score of 1652?

1652 has a Quality Score of 57/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1652 (1652)?

1652 reported trailing-twelve-month revenue of about HK$273M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1652?

The net profit margin of 1652 is about -4.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.